Maraviroc for myositis that has not responded to usual treatments
Tests maraviroc in adults whose myositis did not improve with usual treatments.
Key facts
- Who runs it
- Chinese University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 10 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 31 Aug 2029
- Type of study
- Interventional
- Treatments tested
- maraviroc (Selzentry, Celsentri)
- Record updated
- 30 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active inflammatory muscle disease (myositis) that has not improved with earlier treatments. All participants take Maraviroc 300mg daily for 12 weeks.
- Age
- 18 to under 80 years. The myositis must have started after age 18.
- Sex
- All sexes can join.
- Disease stage
- Idiopathic inflammatory myopathy that meets the 2017 ACR/EULAR criteria. The disease must be active: MMT8 muscle strength score below 142, plus at least two other abnormal measures. These can be patient or doctor activity score of at least 2 cm (0.8 in), a muscle enzyme above 1.5 times the upper normal limit, or HAQ score of at least 0.25.
- Earlier treatment
- The disease must still be active despite glucocorticoids (steroids) plus 2 other immune-suppressing treatments.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Cancer
- Functional class 4 (most severe physical limitation)
- Any medical reason not to take Maraviroc
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- ≥18 to <80 years of age
- Myositis disease onset >18 years
- Fulfillment of 2017 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) IIM classification criteria
- Active myositis defined as Manual Muscle Testing 8 (MMT8) score <142 with at least two other abnormal International Myositis Assessment \& Clinical Studies Group (IMACS) core set measures (Visual Analogue Scale (VAS) of patient global activity ≥2 cm, physician's global disease activity ≥2 cm, at least one muscle enzyme >1.5 times upper limit of normal, Health ssessment Questionnaire(HAQ) ≥0.25), despite 2 additional immunosuppressive treatments on top of glucocorticoids
Who cannot take part
- Malignancy
- Pregnancy or lactation,
- Functional class 4
- Contraindication to Maraviroc
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if the drug Maraviroc works to treat refractory idiopathic inflammatory myopathy (myositis) in patients who have not responded well to traditional therapies. It will also learn about how the drug affects muscle inflammation and function. The main questions it aims to answer are: Does Maraviroc reduce inflammation in the muscles? Does Maraviroc improve patients' muscle function and overall clinical symptoms? This is an open-label study, meaning researchers will give Maraviroc to all participants (there is no placebo) to see if the drug works to treat refractory myositis. Participants will: Take a 300mg Maraviroc tablet every day for 12 weeks. Undergo exams and tests with their doctors to check their muscle function, symptom improvement, and specific health markers (like enzyme levels).
The group in the trial
- Maraviroc groupTreatment being tested
Treatment: maraviroc (Selzentry, Celsentri)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Novel Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies
- Plain-language title
- Maraviroc for myositis that has not responded to usual treatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07668505, who can take part
- Record updated
- 30 June 2026